FindTrial
Sign In

Treating Endometrial Cancer with Precision: A New Era of Personalized Medicine

Molecular profiling of Endometrial Cancer and its impact on designing personalized therapy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/02/104648
Enrollment
50
Registered
2026-02-24
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C548- Malignant neoplasm of overlappingsites of corpus uteri

Interventions

Intervention1: Nil: Nil

Sponsors

none
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Women with histological diagnosis of ca endometrium 2. All histologies including endometrioid or high-risk histology (serous, clear cell, carcinosarcoma and mixed histologies) 3. Planned surgical staging with SLN mapping.

Exclusion criteria

Exclusion criteria: 1.Prior chemotherapy or pelvic radiotherapy. 2. Presence of synchronous malignancies and Recurrent cases 3. Known hypersensitivity to dye 4. Uterine sarcoma

Design outcomes

Primary

MeasureTime frame
1. No of cases with POLE, MMRd, p53 and NSMP profile 2. Number of patients with macro metastasis, micro metastasis and iTC in mapped sentinel nodes 3. Correlation of SLN metastasis among different molecular subtypes. 4. No of patients needing each modality of adjuvant therapy using conventional HPE 5. No of patients needing each modality of adjuvant therapy using molecular profiling Timepoint: 4 weeks—

Secondary

MeasureTime frame
nilTimepoint: nil—

Countries

India

Contacts

Public ContactNutan Sahu

AIIMS, New Delhi

drseemasinghal@gmail.com9818291001

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026